Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma.

Autor: L'Orphelin JM; Department of Dermatology, Caen-Normandie University Hospital, 14033 Caen CEDEX, France., Dollalille C; Department of Cardiology, Caen-Normandie University Hospital, 14033 Caen CEDEX, France., Akroun J; Department of Dermatology, Caen-Normandie University Hospital, 14033 Caen CEDEX, France., Alexandre J; Department of Cardiology, Caen-Normandie University Hospital, 14033 Caen CEDEX, France., Dompmartin A; Department of Dermatology, Caen-Normandie University Hospital, 14033 Caen CEDEX, France.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Apr 06; Vol. 15 (7). Date of Electronic Publication: 2023 Apr 06.
DOI: 10.3390/cancers15072170
Abstrakt: Background: Checkpoint inhibitors, such as PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab), are widely used in metastatic melanoma, and most immune-related adverse events are known. Several cardiovascular AEs (CVAEs) associated with immune checkpoint inhibitor exposure have been reported in post-marketing surveillance studies and represent major issues for patients with melanoma during and after cancer treatment. Data on CVAES induced by immune checkpoint inhibitors in melanoma, especially incidence and risk factors, are lacking.
Methods: A systematic review of the literature up to 31 August 2020 was performed in Medline, the Cochrane Central Register of Controlled Trials (CENTRAL), and the ClinicalTrials.gov register according to prespecified selection criteria from inception to 7 April 2020. Statistics were performed on 3289 patients from five randomized clinical trials on melanoma.
Results: Patients with melanoma treated with immune checkpoint inhibitors had a significant risk of presenting dyslipidemia (Peto OR: 4.74, 95% CI: 2.16-10.41, p < 0.01, I2 = 0%, p = 0.94). The Peto OR was numerically significant for pericarditis, myocarditis, heart failure, myocardial infarction, cerebral ischemia, high pulmonary pressure, blood high pressure, arrhythmias, endocarditis, and conduction disturbances, but the confidence interval was not significant. The risk of CVAEs was not statistically different between melanoma treated with immune checkpoint inhibitors and other tumors treated with immune checkpoint inhibitors (range of p -value from 0.13 to 0.95). No interaction between follow-up length and CVAE reporting was found.
Conclusions: Our study underlines that checkpoint inhibitors used for melanoma increase CVAEs, especially dyslipidemia, which could pave the way to chronic inflammatory processes, atherosclerosis, and, finally, ischemic cardiopathy. These cardiovascular adverse events could be acute or delayed, justifying the monitoring of lipidic biology and a baseline cardiology consultation.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje